RIYADH : The Saudi biotech startups incubated by BADIR Biotechnology Incubator, under the Badir Program, set up by King Abdul Aziz City for Science and Technology (KACST), has successfully raised close to SR38 million ($10.133 million) in new funding last year.
The funding deals were led by venture capital firms, individual investors’ networks and other governmental institutions.
In detail, self-financing accounted for approximately 2.7% of the total amount of investment with financing reaching about SR1 million. The share of individual investment in these projects touched SR2 million, equivalent to 5.3% of the total investment while venture capital companies invested SR35 million, which is equal to 90% of the total amount of financing and investment into biotech startups.
BADIR Biotechnology incubator was established in 2010 within the King Fahd Medical City complex in Riyadh. The incubator works to encourage and support the establishment and development of the biotechnology business sector, through assisting the commercialization of research projects as well as private sector biotechnology innovative products and services. Its aim is to create advanced medical services, support the localization and commercialization of biotechnology and contribute to the advancement of the health sector in the Kingdom.
Nawaf Al Sahhaf, CEO of Badir Program for Technology Incubators and Accelerators, said: “Badir Biotech Incubator aims to encourage and support the launch of new biotechnology projects. The Incubator hosts pioneering projects for researchers, technicians, and doctors in the fields of biotechnology and life sciences, such projects that have the potential to grow into promising and valuable companies in the Kingdom.”
Al-Sahhaf said: “The Biotech Incubator has received over 500 applications since its establishment, and it is currently incubating about 30 technical projects, all of which achieved sales of SR 3.6 million and created more than 136 job opportunities to Saudi young people”.
Al Sahhaf further added: “We look forward to supporting Biotech startups which have the basic factors that enable them to make quantitative changes in the main technology sectors. We expect a rise in the average of establishing and funding this type of companies in the coming years, especially following the adoption of new alternatives for offering flexible funding opportunities, hence assisting them in developing their investment plans and increasing their future expansions.”
Badir Program is one of the leading programs of King Abdulaziz City for Science and Technology. The program was established in 2008 to improve and support technical entrepreneurship throughout the Kingdom by helping the strategic policy applied in entrepreneurship and incubators in collaboration with government agencies, universities and the private sector.
-Ends-
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
